Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;60(5):385-397.
doi: 10.1002/gcc.22935. Epub 2021 Jan 11.

PARP inhibitors in ovarian cancer: An overview of the practice-changing trials

Tiffany Foo  1   2 , Angela George  1   2 , Susana Banerjee  1   3
Affiliations
Review

PARP inhibitors in ovarian cancer: An overview of the practice-changing trials

Tiffany Foo et al. Genes Chromosomes Cancer. 2021 May.

Abstract

Poly (ADP-ribose) polymerase (PARP) inhibitors have transformed the management of recurrent ovarian cancer in patients with BRCA-mutations and beyond. Olaparib was the first PARP inhibitor to gain approval as maintenance therapy for patients with newly diagnosed, advanced BRCA-mutated ovarian cancer establishing a new standard of care. At the end of 2020, as a result of the SOLO1, PRIMA, and PAOLA-1 phase III trials, we are now in an era where three maintenance PARP inhibitor strategies have FDA and European Medicines Agency approval in the first-line setting. In this review, we provide an overview of the key PARP inhibitor trials that have changed clinical practice, discuss directing therapy according to biomarker status (BRCA and homologous recombination deficiency) and future strategies in ovarian cancer and other gynecological malignancies.

Keywords: BRCA; HRD; PARP inhibitors; maintenance therapy; ovarian cancer.

PubMed Disclaimer

References

REFERENCES

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492.
    1. Ovarian Cancer-Cancer Stat Facts. Accessed July 1, 2020. https://seer.cancer.gov/statfacts/html/ovary.html.
    1. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up †. ESMO Update Clin Pract Guideline. 2013;24:vi24-vi32. https://doi.org/10.1093/annonc/mdt333.
    1. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473-2483. https://doi.org/10.1056/NEJMoa1104390.
    1. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484-2496. https://doi.org/10.1056/NEJMoa1103799.

Publication types

MeSH terms

Substances

LinkOut - more resources